|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Administration of TAP siRNA conjugated to a broad-range tumor-targeting nucleolin aptamer inhibited tumor growth in multiple tumor models without measurable toxicity, was comparatively effective to vaccination against prototypic mutation-generated neoantigens, potentiated the antitumor effect of PD-1 antibody or Flt3 ligand, and induced the presentation of a TAP-independent peptide in human tumor cells.
|
31434881 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Similarly, the Aldefluor<sup>+</sup> population of patient tumors and 4T1 murine mammary cells had decreased expression of TAP and co-stimulatory molecule genes.
|
29341428 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the JDCaP xenograft model, TAK-448-SR(1M) and TAK-683-SR(1M) both showed better prostate-specific antigen (PSA) control than TAP-144-SR(1M), although all treatment groups eventually experienced PSA recurrence and tumor regrowth.
|
29355559 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among them, TAP-07 and TP-07 presented cytotoxic activity in all tumor cell lines, including HepG2 (IC<sub>50</sub> 2.2 and 5.6μM, respectively) without antiproliferative effects to normal cells (PBMC) (IC<sub>50</sub>>30μM), making TAP-07 and TP-07, the compounds with the most favorable selectivity index.
|
28610992 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, the ppCT(16-25) human tumor epitope requires low TAP expression for efficient presentation.
|
23302073 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, individuals with nonfunctional TAP complexes or tumor or infected cells with blocked TAP molecules are able to present HLA class I ligands generated by TAP-independent processing pathways.
|
22298786 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genome-scale TSA search was conducted by genome-scale search of tumor-specific mutations in differentially over-expressed genes of specific cancers based on tumor-specific somatic mutation and microarray gene expression data, followed by T-cell recognition analysis of the identified mutant and over-expressed peptides to determine if they are substrates of proteasomal cleavage, TAP mediated transport and MHC-I alleles capable of eliciting immune response.
|
19243822 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic variants in TAP are associated with high-grade cervical neoplasia.
|
19188174 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This is the first demonstration that Tpn alone can enhance survival and immunity against tumors but additionally suggests that Tpn and TAP should be used together as components of immunotherapeutic vaccine protocols to eradicate tumors.
|
18316574 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results show that TAP should be considered as a part of the immunotherapies for various cancers because it is likely to provide a general method for increasing immune responses against tumors regardless of the antigenic composition of the tumor or the MHC haplotypes of the host.
|
16140964 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Polymerase chain reaction based protocols were used to examine HLA class I and TAP genes in a panel of cervical tumours, using DNA from corresponding blood samples as controls.
|
14984960 |
2004 |